MD107C2 - Transdermal therapeutical system - Google Patents

Transdermal therapeutical system

Info

Publication number
MD107C2
MD107C2 MD94-0095A MD940095A MD107C2 MD 107 C2 MD107 C2 MD 107C2 MD 940095 A MD940095 A MD 940095A MD 107 C2 MD107 C2 MD 107C2
Authority
MD
Moldova
Prior art keywords
physostigmine
weight
layer
base
reservoir layer
Prior art date
Application number
MD94-0095A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD107B1 (en
Inventor
Hille Thomas
Hoffmann Hans-Rainer
Knoch Axel
Huber Hans-Joachim
Schneider Gerhard
Stanislaus Fritz
Original Assignee
Klinge Pharma Gmbh
Lts Lohmann Therapie-Systeme Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE3843239A external-priority patent/DE3843239C1/de
Application filed by Klinge Pharma Gmbh, Lts Lohmann Therapie-Systeme Gmbh & Co.Kg filed Critical Klinge Pharma Gmbh
Publication of MD107B1 publication Critical patent/MD107B1/en
Publication of MD107C2 publication Critical patent/MD107C2/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

The invention relates to the medicine especially to the transdermal therapeutical system, which contains physostigmine as an active component part. The purpose of the invention consists in the increasing of time of cheeking casualness of physostigmine and of its stability at the system keeping.The system is constituted from unpenetrable tegumental layer for active substance, stocky reservoir layer, in case of necessity from protecting layer of detachment. Reservoir layer contains 67-90% weight of polymer material from block copolymer group on styrene base and 1,3 diene, polyisobutylene, polymer on acrylate base and/or mateckylate and complex ethers of hydrogenated calophonium, as well as 10-25% weight of softener on hydrocarbon base and/or complex ethers and 6,3-11,7% weight of physostigmine.
MD94-0095A 1988-12-22 1994-04-28 Transdermal therapeutical system MD107C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3843239A DE3843239C1 (en) 1988-12-22 1988-12-22
SU894742793A RU2011384C1 (en) 1988-12-22 1989-12-21 Transdermal therapeutic system

Publications (2)

Publication Number Publication Date
MD107B1 MD107B1 (en) 1994-12-31
MD107C2 true MD107C2 (en) 1995-07-31

Family

ID=25875486

Family Applications (1)

Application Number Title Priority Date Filing Date
MD94-0095A MD107C2 (en) 1988-12-22 1994-04-28 Transdermal therapeutical system

Country Status (2)

Country Link
LV (1) LV5578A3 (en)
MD (1) MD107C2 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cererea nr. 3606892, DE, A 61 K 31/465, A 61 K 31/44, 1988. *

Also Published As

Publication number Publication date
MD107B1 (en) 1994-12-31
LV5578A3 (en) 1994-05-10

Similar Documents

Publication Publication Date Title
AU743229C (en) Transdermal therapeutic system containing pergolide
GR3017851T3 (en) Dressing containing estrogen.
CA2034934A1 (en) Transdermal Therapeutic System Comprising Tulobuterol as Active Substance
MY100066A (en) Multicompartmentalized dermal and transdermal patches.
YU47076B (en) PROCEDURE FOR DEVELOPING A TRANSDERMAL THERAPEUTIC SYSTEM WITH PHYSOSTIGMIN AS AN ACTIVE INGREDIENT
YU47077B (en) PROCEDURE FOR DEVELOPING A TRANSDERMAL THERAPEUTIC SYSTEM WITH PHYSOSTIGMIN AS AN ACTIVE INGREDIENT
MY105347A (en) Transdermal therapeutic system comprising as active component buprenorphine
WO1998002147A3 (en) Transdermal therapeutic systems
BG102322A (en) Transdermal matrix system
MD107C2 (en) Transdermal therapeutical system
DK0737475T3 (en) Use of a muscarinic antagonist for the manufacture of a medicament for the treatment and regulation of ocular development
CA2137961A1 (en) Cyclic depsipeptides having 18 ring atoms, and their use for combating endoparasites
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
MD348C2 (en) Transdermal therapeutic system and method for obtaining thereof
BG102182A (en) The use of ipriflavon for reducing the number of cd8+ cells
MX9804137A (en) METHODS FOR DETERMINING COMPOUNDS CAPABLE OF INHIBITING THE ACTIVITIES OF THE Ha-ras ONCOGENE.

Legal Events

Date Code Title Description
FG4A Patent for invention issued
IF99 Valid patent on 19990615

Free format text: EXPIRES: 20090427